EU Nephrologists Foresee Travere/CSL Vifor’s FILSPARITM (sparsentan) Transforming IgA Nephropathy Treatment as the First Non-Immunosuppressive Therapy EXTON, PA, April 30, 2024 (GLOBE NEWSWIRE) -- Over the past several years, glomerular diseases have garnered significant attention from the nephrology industry, largely driven by the persistent...

Use of SGLT2 Inhibitors Continues to Expand for the Treatment of Chronic Kidney Disease, with Eli Lilly/Boehringer Ingelheim’s Jardiance Making Significant Strides Following Label Expansion EXTON, PA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Since 2019, audited records of chronic kidney disease (CKD) non-dialysis patients has revealed an ongoing, annual uptick in the proportion of...

Global SGLT2 Inhibitors Treatment Market to Grow at a Notable CAGR During 2022-2031; Improved Healthcare System, and Growing Prevalence of Chronic Diseases Worldwide to Drive the Market Growth New York, July 20, 2022 (GLOBE NEWSWIRE) -- In 2019, diabetes was the ninth leading cause of death with an estimated 1.5 million deaths directly caused by diabetes. Furthermore, about 422 million...

Diabetes Drugs Market to Reach US$ 78,261.7 Mn by 2026, Deriving Growth from Increasing Drug Approvals, says Fortune Business Insights Pune, June 26, 2019 (GLOBE NEWSWIRE) -- The global Diabetes Drugs Market derives growth from advancements in drug delivery systems. According to a report published by Fortune Business Insights,...

SGLT2 Inhibitors a Promising New Therapy for Type II Diabetes: New Cutting Edge Information Report Analyzes Diabetes Market Forecast Through 2013 RESEARCH TRIANGLE PARK, NC--(Marketwire - December 12, 2008) - A new drug class is poised to make a splash in the diabetes market, according to a new report, "Diabetes Market Forecast to...